GlassScriptPhysician profile
Raafat Issa
NPI 1750497483
$9,903.82
in general payments reported to CMS, 2019-2025
36 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $784 · 2021: $1,199 · 2022: $1,651 · 2023: $2,171 · 2024: $1,413 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,075.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,272.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,183.22 | 2021-2025 | |
| Novo Nordisk INC | $921.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $826.81 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $826.36 | 2019-2025 | |
| Lilly USA, LLC | $525.69 | 2019-2025 | Mounjaro, Zepbound, Reyvow |
| Abbott Laboratories | $516.72 | 2021-2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $441.73 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $381.51 | 2021-2025 | Repatha, Otezla, Repatha |
| Acadia Pharmaceuticals INC | $223.63 | 2022-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $213.11 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.09 | 2019-2024 | Jardiance, Ofev |
| Neurocrine Biosciences, INC. | $191.52 | 2022-2023 | Ingrezza |
| Regeneron Healthcare Solutions, INC. | $117.93 | 2023 | Dupixent |
| Exact Sciences Corporation | $114.40 | 2023-2025 | Cologuard Collection Kit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $99.66 | 2019-2021 | |
| Lundbeck LLC | $83.05 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $81.85 | 2023-2025 | |
| Verona Pharma, INC. | $81.75 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company LTD. | $77.37 | 2022 | |
| Horizon Therapeutics Plc | $67.00 | 2022-2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $59.87 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $54.50 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $52.73 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $42.49 | 2023 | Contrave |
| Bausch Health US, LLC | $38.57 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $32.37 | 2024-2025 | Opsumit, Uptravi |
| Biohaven Pharmaceuticals, INC. | $28.50 | 2021 | |
| Boston Scientific Corporation | $25.60 | 2023 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $20.32 | 2021 | |
| Gilead Sciences, INC. | $19.74 | 2025 | |
| Pulmonx Corporation | $19.14 | 2024 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| E.R. Squibb & Sons, L.L.C. | $17.58 | 2023 | Eliquis |
| Dexcom, INC. | $16.39 | 2021 | |
| Inari Medical, INC. | $14.04 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shire North American Group INC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raafat Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.